Base de dados : MEDLINE
Pesquisa : D27.505.696.282.050 [Categoria DeCS]
Referências encontradas : 457 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 46 ir para página                         

  1 / 457 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28056951
[Au] Autor:Zollers B; Rhodes L; Heinen E
[Ad] Endereço:Norbrook Inc., Lenexa, KS, USA.
[Ti] Título:Capromorelin oral solution (ENTYCE®) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study.
[So] Source:BMC Vet Res;13(1):10, 2017 Jan 05.
[Is] ISSN:1746-6148
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Dogs can suffer from inappetence caused by a variety of medical conditions. This may present as anorexia (complete loss of appetite), hyporexia (decreased appetite) or dysrexia (change in food preferences). A drug with a new mechanism of action, capromorelin, has potential to stimulate appetite in dogs. Capromorelin is a ghrelin receptor agonist, which mimics the action of endogenous ghrelin. It is a member of the growth hormone secretagogue (GHS) class of drugs. Capromorelin oral solution (ENTYCE®) was tested in healthy adult male and female Beagle dogs (n = 6 males and 6 females per group) for its effect on food consumption and body weight. A randomized, masked, placebo controlled study was conducted to measure the effects of a daily 3 mg/kg oral dose given over 4 days. Dogs were observed for clinical signs, physical examinations were completed prior to and at the end of treatment, and blood was drawn before and after treatment for evaluation of serum chemistry and hematology parameters. RESULTS: Capromorelin was well-tolerated, with no abnormalities seen on physical examination or clinical pathology. Some dogs showed increased salivation. Capromorelin treated dogs had increased mean (±SD) food consumption compared to placebo treated dogs (60.55 ± 39.87% versus -11.15 ± 14.23% respectively, P < 0.001). Treated dogs also had increased mean body weights compared to placebo treated dogs (5.96 ± 1.76% versus 0.053 ± 1.14% respectively, P < 0.001). CONCLUSIONS: This study supports the effectiveness of capromorelin oral solution as an appetite stimulant in dogs. Treatment with the oral solution resulted in dramatic increases in appetite, as measured by food consumption, of over 60% compared to placebo. The drug was well tolerated. Capromorelin is the first ghrelin receptor agonist developed for appetite stimulation in any species, and represents a novel mechanism of action for this clinical use.
[Mh] Termos MeSH primário: Estimulantes do Apetite/farmacologia
Peso Corporal/efeitos dos fármacos
Ingestão de Alimentos/efeitos dos fármacos
Piperidinas/farmacologia
Pirazóis/farmacologia
[Mh] Termos MeSH secundário: Animais
Estimulantes do Apetite/administração & dosagem
Estudos Cross-Over
Cães
Feminino
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Appetite Stimulants); 0 (CP 424391); 0 (Piperidines); 0 (Pyrazoles)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE
[do] DOI:10.1186/s12917-016-0925-z


  2 / 457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27639080
[Au] Autor:Guk J; Son H; Chae DW; Park K
[Ad] Endereço:Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:Quantitative Assessment of Food Effect on the Pharmacokinetics of Nano-Crystallized Megestrol Acetate.
[So] Source:Basic Clin Pharmacol Toxicol;120(3):270-277, 2017 Mar.
[Is] ISSN:1742-7843
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Megestrol acetate, an appetite stimulant with low bioavailability, shows increased bioavailability when taken together with food. However, the pharmacokinetic characteristics of megestrol acetate and its relation with food are not well understood. This study aimed to investigate the food effect on the pharmacokinetics (PK) of the recently developed nano-crystallized megestrol acetate (NCMA), using a model-based approach. Data were obtained from an NCMA PK study consisting of a single dose in fasting (39 individuals) and fed conditions (40 individuals). Plasma concentrations were measured up to 120 hr after dosing. With the incorporation of body-weight via allometry, NONMEM 7.3 was used to develop a PK model, which was then used to simulate an optimal fasting dose yielding an area under concentration (AUC) and maximum concentration (C ) of NCMA close to those obtained with the fed dose. NCMA concentrations were best characterized by a two-compartment model with first-order absorption linked to a recycling compartment to account for the multiple concentration peaks observed. Food increased bioavailability 2.2 times and decreased the absorption rate constant 0.58 times. Recycling event times were estimated to be 3.56, 7.99 and 24.0 hr. The optimal fast dose was 2.0 times higher than the fed dose, and the resulting difference in drug exposure between the fasting and fed dose was 7.5%. This work suggests that the PK model developed can be applied to an optimal dosage regimen design for NCMA treatment.
[Mh] Termos MeSH primário: Estimulantes do Apetite/administração & dosagem
Estimulantes do Apetite/farmacocinética
Interações Alimento-Droga
Acetato de Megestrol/administração & dosagem
Acetato de Megestrol/farmacocinética
Modelos Biológicos
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Estimulantes do Apetite/uso terapêutico
Disponibilidade Biológica
Caquexia/tratamento farmacológico
Estudos Cross-Over
Sistemas de Liberação de Medicamentos/métodos
Cálculos da Dosagem de Medicamento
Ingestão de Alimentos
Jejum
Voluntários Saudáveis
Seres Humanos
Masculino
Acetato de Megestrol/uso terapêutico
Nanopartículas
República da Coreia
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Appetite Stimulants); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170302
[Lr] Data última revisão:
170302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160918
[St] Status:MEDLINE
[do] DOI:10.1111/bcpt.12677


  3 / 457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26979077
[Au] Autor:Wu W; Zhou HR; Pestka JJ
[Ad] Endereço:College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, People's Republic of China.
[Ti] Título:Potential roles for calcium-sensing receptor (CaSR) and transient receptor potential ankyrin-1 (TRPA1) in murine anorectic response to deoxynivalenol (vomitoxin).
[So] Source:Arch Toxicol;91(1):495-507, 2017 Jan.
[Is] ISSN:1432-0738
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Food contamination by the trichothecene mycotoxin deoxynivalenol (DON, vomitoxin) has the potential to adversely affect animal and human health by suppressing food intake and impairing growth. In mice, the DON-induced anorectic response results from aberrant satiety hormone secretion by enteroendocrine cells (EECs) of the gastrointestinal tract. Recent in vitro studies in the murine STC-1 EEC model have linked DON-induced satiety hormone secretion to activation of calcium-sensing receptor (CaSR), a G-coupled protein receptor, and transient receptor potential ankyrin-1 (TRPA1), a TRP channel. However, it is unknown whether similar mechanisms mediate DON's anorectic effects in vivo. Here, we tested the hypothesis that DON-induced food refusal and satiety hormone release in the mouse are linked to activation of CaSR and TRPA1. Oral treatment with selective agonists for CaSR (R-568) or TRPA1 (allyl isothiocyanate (AITC)) suppressed food intake in mice, and the agonist's effects were suppressed by pretreatment with corresponding antagonists NPS-2143 or ruthenium red (RR), respectively. Importantly, NPS-2143 or RR inhibited both DON-induced food refusal and plasma elevations of the satiety hormones cholecystokinin (CCK) and peptide YY (PYY ); cotreatment with both antagonists additively suppressed both anorectic and hormone responses to DON. Taken together, these in vivo data along with prior in vitro findings support the contention that activation of CaSR and TRPA1 contributes to DON-induced food refusal by mediating satiety hormone exocytosis from EEC.
[Mh] Termos MeSH primário: Anorexia/induzido quimicamente
Depressores do Apetite/toxicidade
Poluentes Ambientais/toxicidade
Modelos Biológicos
Receptores Acoplados a Proteínas-G/agonistas
Canais de Receptores Transientes de Potencial/agonistas
Tricotecenos/toxicidade
[Mh] Termos MeSH secundário: Animais
Anorexia/metabolismo
Anorexia/prevenção & controle
Depressores do Apetite/química
Estimulantes do Apetite/uso terapêutico
Comportamento Animal/efeitos dos fármacos
Colecistocinina/agonistas
Colecistocinina/antagonistas & inibidores
Colecistocinina/sangue
Quimioterapia Combinada
Ingestão de Energia/efeitos dos fármacos
Poluentes Ambientais/antagonistas & inibidores
Feminino
Fragmentos de Peptídeos/agonistas
Fragmentos de Peptídeos/antagonistas & inibidores
Fragmentos de Peptídeos/sangue
Peptídeo YY/agonistas
Peptídeo YY/antagonistas & inibidores
Peptídeo YY/sangue
Distribuição Aleatória
Receptores Acoplados a Proteínas-G/antagonistas & inibidores
Receptores Acoplados a Proteínas-G/metabolismo
Resposta de Saciedade/efeitos dos fármacos
Canal de Cátion TRPA1
Canais de Receptores Transientes de Potencial/antagonistas & inibidores
Canais de Receptores Transientes de Potencial/metabolismo
Tricotecenos/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Appetite Depressants); 0 (Appetite Stimulants); 0 (CASR protein, mouse); 0 (Environmental Pollutants); 0 (Peptide Fragments); 0 (Receptors, G-Protein-Coupled); 0 (TRPA1 Cation Channel); 0 (Transient Receptor Potential Channels); 0 (Trichothecenes); 0 (Trpa1 protein, mouse); 106388-42-5 (Peptide YY); 123583-37-9 (peptide YY (3-36)); 9011-97-6 (Cholecystokinin); JT37HYP23V (deoxynivalenol)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160317
[St] Status:MEDLINE
[do] DOI:10.1007/s00204-016-1687-x


  4 / 457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27843307
[Au] Autor:Ghobadi H; Matin S; Nemati A; Naghizadeh-Baghi A
[Ad] Endereço:Pulmonary Division.
[Ti] Título:The effect of conjugated linoleic acid supplementation on the nutritional status of COPD patients.
[So] Source:Int J Chron Obstruct Pulmon Dis;11:2711-2720, 2016.
[Is] ISSN:1178-2005
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: COPD patients are susceptible to anorexia, reduction of caloric intake, weight loss, and malnutrition. One of the possible mechanisms is the increase of inflammatory markers such as interleukin 1ß (IL ), is highly correlated with anorexia. Considering the anti-inflammatory role of conjugated linoleic acid (CLA), this study aimed to investigate the effect of CLA supplementation on the nutritional status of COPD patients. PATIENTS AND METHODS: In a double-blind clinical trial, 93 COPD patients who volunteered to participate in the study and who filled out a written consent form, were randomly assigned to control or supplementation groups. The patients in the supplementation group received 3.2 g of CLA on a daily basis for 6 weeks, while those in the control group received placebo on a daily basis for 6 weeks. For IL assessment, the patients' anthropometric indices and appetite score were checked and their blood samples were collected both before and after the treatment. Moreover, in order to investigate the changes in the caloric intake trend during the study, their dietary intake levels were assessed using 24-hour dietary recall, 3 days a week at the onset, in the 4th week, and at the end of the study. Eventually, 90 patients completed the study. RESULTS: The results demonstrated a significant increase in appetite score ( =0.001), average caloric intake ( =0.01), and macronutrient intake ( <0.05), while a significant decrease was observed in the serum level of IL among the patients of the supplementation group ( =0.008). Meanwhile, although the supplementation group's body mass index was also higher on completion, compared to their own initial state as well as to that in the control group, the differences were not significant ( =0.13). CONCLUSION: The findings of this research indicate that the consumption of CLA supplementation can be effective in regulating the appetite and improving the nutritional status of patients suffering from COPD through adjusting the serum level of IL .
[Mh] Termos MeSH primário: Regulação do Apetite/efeitos dos fármacos
Estimulantes do Apetite/uso terapêutico
Ácidos Linoleicos Conjugados/uso terapêutico
Estado Nutricional/efeitos dos fármacos
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Estimulantes do Apetite/efeitos adversos
Biomarcadores/sangue
Índice de Massa Corporal
Registros de Dieta
Suplementos Nutricionais/efeitos adversos
Método Duplo-Cego
Ingestão de Energia/efeitos dos fármacos
Volume Expiratório Forçado
Seres Humanos
Mediadores da Inflamação/sangue
Interleucina-1beta/sangue
Irã (Geográfico)
Ácidos Linoleicos Conjugados/efeitos adversos
Pulmão/fisiopatologia
Masculino
Meia-Idade
Doença Pulmonar Obstrutiva Crônica/sangue
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Appetite Stimulants); 0 (Biomarkers); 0 (IL1B protein, human); 0 (Inflammation Mediators); 0 (Interleukin-1beta); 0 (Linoleic Acids, Conjugated)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161116
[St] Status:MEDLINE


  5 / 457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27582336
[Au] Autor:Ogawa K; Ito M
[Ad] Endereço:Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Kyoto University.
[Ti] Título:Appetite-Enhancing Effects of Curry Oil.
[So] Source:Biol Pharm Bull;39(9):1559-63, 2016.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Inhalation of scent compounds with phenylpropanoidal structures, such as trans-cinnamaldehyde, is expected to increase the appetite. The scent of curry powder is well known for its appetite-enhancing effect on humans. In this work, we show that the appetite of mice after inhalation of curry powder essential oil or benzylacetone showed a similar increase. The components of curry oil, trans-cinnamaldehyde, trans-anethole, and eugenol, each showed appetite-enhancing effects; therefore, these three scent compounds may be the active compounds in curry powder oil.
[Mh] Termos MeSH primário: Acroleína/análogos & derivados
Anisóis/farmacologia
Estimulantes do Apetite/farmacologia
Eugenol/farmacologia
Gengibre
Óleos Voláteis/farmacologia
Especiarias
[Mh] Termos MeSH secundário: Acroleína/análise
Acroleína/farmacologia
Animais
Anisóis/análise
Apetite/efeitos dos fármacos
Estimulantes do Apetite/análise
Eugenol/análise
Masculino
Camundongos
Óleos Voláteis/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anisoles); 0 (Appetite Stimulants); 0 (Oils, Volatile); 3T8H1794QW (Eugenol); 7864XYD3JJ (Acrolein); Q3JEK5DO4K (anethole); SR60A3XG0F (cinnamic aldehyde)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170206
[Lr] Data última revisão:
170206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160902
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b16-00351


  6 / 457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27387211
[Au] Autor:Stanska K; Krzeski A
[Ad] Endereço:Klinika Otorynolaryngologii, Wydzial Lekarsko-Dentystyczny Warszawski Uniwersytet Medyczny. Szpital Czerniakowski ul. Stepinska 19/25 00-739 Warszawa / Department of Otorhinolaryngology, Medical University of Warsaw, 19/25 Stepinska Street, 00-739 Warsaw.
[Ti] Título:The umami taste: from discovery to clinical use.
[So] Source:Otolaryngol Pol;70(4):10-5, 2016 Jun 30.
[Is] ISSN:2300-8423
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:In the diversity of the flavor world only five basic tastes have been described. The newest one, umami, has been identified about one hundred years ago by Kikunae Ikeda but widely accepted just in the second half of the twentieth century by international scientific world. There are three umami substances: monosodium glutamate (MSG), inosine-5'-monophosphate (IMP), guanylo-5'-monophosphate (GMP). A real breakthrough in umami history concerned the finding about independent receptors for umami: T1R1 and T1R3 (taste receptors type 1 member 1 and member 3). The palatable, delicious taste of umami and its mechanism determined a lot of research studies on this highlight. Umami substances elicit salivary secretion, enhance appetite and increase food palatability. They are desirable to improve the quality of diet. Moreover, the association between umami substances and the suppression of obesity has been found. Studies suggest that umami is engaged in metabolism but also increases satiety and reduces the post-ingestive recovery of hunger.
[Mh] Termos MeSH primário: Aromatizantes/metabolismo
Aditivos Alimentares/metabolismo
Guanosina Monofosfato/metabolismo
Inosina Monofosfato/metabolismo
Glutamato de Sódio/metabolismo
Papilas Gustativas/fisiologia
[Mh] Termos MeSH secundário: Estimulantes do Apetite/metabolismo
Comportamento Alimentar
Seres Humanos
Paladar/efeitos dos fármacos
Língua/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Appetite Stimulants); 0 (Flavoring Agents); 0 (Food Additives); 131-99-7 (Inosine Monophosphate); 85-32-5 (Guanosine Monophosphate); W81N5U6R6U (Sodium Glutamate)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170428
[Lr] Data última revisão:
170428
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160709
[St] Status:MEDLINE
[do] DOI:10.5604/00306657.1199991


  7 / 457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27191767
[Au] Autor:Chae DW; Son H; Guk J; Park C; Park K
[Ti] Título:Pharmacokinetics of a nanocrystal-containing megestrol acetate formulation: a single-dose, randomized, open-label, 2-part, 2-period crossover study in healthy Korean subjects.
[So] Source:Int J Clin Pharmacol Ther;54(9):698-704, 2016 Sep.
[Is] ISSN:0946-1965
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: OBJECTIVE: The conventional suspension of megestrol acetate contains micronized megestrol acetate, which was recently discovered to have a disadvantage of decreasing bioavailability when taken in a fasting state. Since megestrol acetate is taken to increase appetite, this property becomes a discouraging factor. To improve upon this, an advanced formulation was developed using a nanocrystal drug-delivery system. This study was conducted to compare the safety and pharmacokinetic characteristics between the conventional formulation of megestrol acetate and a generic version of the advanced formulation containing nanocrystals. METHODS: This was a randomized, open-label, 2-period, 2-treatment, crossover, single-dose, 2-part study (part 1 fasting and part 2 fed), conducted in healthy males aged between 20 and 50 years with weight within ± 20% of ideal body weight having no congenital abnormalities or chronic diseases. Different subjects were used in part 1 and part 2, but subjects received a single dose of the reference and test drugs separated by a 14-day washout period. Blood sampling was performed up to 120 hours after dosing using a pre-specified sampling time scheme. Primary pharmacokinetic parameters were Cmax and AUClast of the test and reference formulations of megestrol acetate. Bioequivalence evaluation was based on the standard criterion of 80 - 125% for the 90% confidence interval of geometric mean ratios of test to reference drugs calculated for the pharmacokinetic parameters. To monitor adverse events, both subject interviews and physical examinations were done on a regular time basis. RESULTS: 80 subjects (n = 40 each part) were enrolled, and 79 completed the study. The 90% CIs of the geometric mean ratios of Cmax and AUClast were 4.4625 - 5.6018 and 1.3602 - 1.6418, respectively, for part 1, and 0.9793 - 1.1327 and 0.7721 - 0.8431, respectively, for part 2. No significant difference was discovered in the incidence of adverse events (AEs) when test and reference treated groups were compared. CONCLUSIONS: Our findings suggest that the test formulation of megestrol-acetate-containing nanocrystals is better absorbed and has higher bioavailability compared to the reference formulation in a fasting state. This should allow for a lower dose and better patient compliance.

ClinicalTrials.gov identifier: NCT02446353.
[Mh] Termos MeSH primário: Estimulantes do Apetite/farmacocinética
Medicamentos Genéricos/farmacocinética
Acetato de Megestrol/farmacocinética
Nanopartículas
[Mh] Termos MeSH secundário: Adulto
Estimulantes do Apetite/administração & dosagem
Área Sob a Curva
Grupo com Ancestrais do Continente Asiático
Disponibilidade Biológica
Estudos Cross-Over
Sistemas de Liberação de Medicamentos
Medicamentos Genéricos/administração & dosagem
Medicamentos Genéricos/efeitos adversos
Jejum
Seres Humanos
Masculino
Acetato de Megestrol/administração & dosagem
Acetato de Megestrol/efeitos adversos
Meia-Idade
Equivalência Terapêutica
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Appetite Stimulants); 0 (Drugs, Generic); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170203
[Lr] Data última revisão:
170203
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160519
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.5414/CP202574


  8 / 457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27150149
[Au] Autor:Ogawa K; Ito M
[Ad] Endereço:Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Kyoto University.
[Ti] Título:Appetite-Enhancing Effects: The Influence of Concentrations of Benzylacetone and trans-Cinnamaldehyde and Their Inhalation Time, as Well as the Effect of Aroma, on Body Weight in Mice.
[So] Source:Biol Pharm Bull;39(5):794-8, 2016.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Benzylacetone has appetite-enhancing and locomotor-reducing effects. The effective doses for these two outcomes overlap, and the weight gain of mice exposed to benzylacetone is caused by both appetite-enhancement and a reduction in locomotor activity. The appetite-enhancing effects of trans-cinnamaldehyde and benzylacetone have been reported previously. In this study, these appetite-enhancing effects were seen in mice after short-term, high-dose exposure.
[Mh] Termos MeSH primário: Acetona/análogos & derivados
Acroleína/análogos & derivados
Estimulantes do Apetite/administração & dosagem
Apetite/efeitos dos fármacos
[Mh] Termos MeSH secundário: Acetona/administração & dosagem
Acetona/farmacologia
Acroleína/administração & dosagem
Acroleína/farmacologia
Administração por Inalação
Animais
Estimulantes do Apetite/farmacologia
Peso Corporal/efeitos dos fármacos
Relação Dose-Resposta a Droga
Masculino
Camundongos
Atividade Motora/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Appetite Stimulants); 0 (benzyl acetone); 1364PS73AF (Acetone); 7864XYD3JJ (Acrolein); SR60A3XG0F (cinnamic aldehyde)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170127
[Lr] Data última revisão:
170127
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160507
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b15-00937


  9 / 457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26537025
[Au] Autor:Smith CS; Logomarsino JV
[Ad] Endereço:Division of Nephrology, Levine Children's Hospital-Carolinas Healthcare System, Charlotte, North Carolina, USA.
[Ti] Título:Using megestrol acetate to ameliorate protein-energy wasting in chronic kidney disease.
[So] Source:J Ren Care;42(1):53-9, 2016 Mar.
[Is] ISSN:1755-6686
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Various populations are affected by chronic kidney disease (CKD), and a low dose appetite stimulant megestrol acetate (MA) is sometimes recommended in patients with CKD to ameliorate protein-energy wasting (PEW). Patients with CKD are at greater risk of developing PEW since the progression of their disease can cause decreased nutrient intake, catabolic effects, systemic inflammation and metabolic changes. Providers can detect PEW in CKD by identifying low serum levels ≤3.8 g/dl of albumin, <30 mg/dl of transthyretin, or <100 mg/dl of cholesterol. Other characteristics include BMI <22 kg/m(2) (for ≤65 years), unintentional weight loss of ≥5% in three months or ≥10% in six months, body fat percentage <10%, with muscle wasting of a reduction of ≥5% in three months or ≥10% in six months of muscle mass. METHOD: A review of research was completed and data collected from small population-based retrospective studies to determine the effect of MA. RESULTS: Clinical trials demonstrated the effectiveness of MA by showing increases in BMI up to 9%, albumin levels up to 1.1 g/dl, with reported protein and energy intake increases from 27% to 42%. There are potential adverse effects of using MA in CKD. CONCLUSION: After reviewing the available literature, the benefits of using MA should be evaluated against the potential side effects. For further examination of MA's potential benefits, long-term, prospective, large clinical trials should be carried out.
[Mh] Termos MeSH primário: Estimulantes do Apetite/uso terapêutico
Acetato de Megestrol/uso terapêutico
Desnutrição Proteico-Calórica/tratamento farmacológico
Insuficiência Renal Crônica/complicações
Síndrome de Emaciação/tratamento farmacológico
[Mh] Termos MeSH secundário: Estimulantes do Apetite/efeitos adversos
Seres Humanos
Acetato de Megestrol/efeitos adversos
Desnutrição Proteico-Calórica/etiologia
Insuficiência Renal Crônica/tratamento farmacológico
Síndrome de Emaciação/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Appetite Stimulants); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170216
[Lr] Data última revisão:
170216
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:151106
[St] Status:MEDLINE
[do] DOI:10.1111/jorc.12138


  10 / 457 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26228539
[Au] Autor:Ferguson LE; McLean MK; Bates JA; Quimby JM
[Ad] Endereço:1 Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
[Ti] Título:Mirtazapine toxicity in cats: retrospective study of 84 cases (2006-2011).
[So] Source:J Feline Med Surg;18(11):868-874, 2016 Nov.
[Is] ISSN:1532-2750
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives Mirtazapine is commonly used in veterinary medicine at doses of 1.88 or 3.75 mg as an appetite stimulant. The objectives of this study were to determine the most common adverse effects reported and the dose associated with these signs. Methods Records of cats with mirtazapine exposure (2006-2011) were obtained from the American Society for the Prevention of Cruelty to Animals' Animal Poison Control Center. The following parameters were recorded: signalment, weight, outcome, agent ingested, amount ingested, route of exposure, clinical signs observed, intended of use, onset time of signs and duration of signs. Results The 10 most commonly observed adverse effects reported in 84 cats exposed to mirtazapine included vocalization (56.0% of cats; mean dose 2.56 mg/kg), agitation (31.0%; 2.57 mg/kg), vomiting (26.2%; 2.92 mg/kg), abnormal gait/ataxia (16.7%; 2.87 mg/kg), restlessness (14.3%; 3.55 mg/kg), tremors/trembling (14.3%; 2.43 mg/kg), hypersalivation (13.0%; 2.89 mg/kg), tachypnea (11.9%; 3.28 mg/kg), tachycardia (10.7%; 3.04 mg/kg) and lethargy (10.7%; 2.69 mg/kg). Fifty-nine (70.2%) cases were considered accidental ingestions and 25 (29.8%) cases were given mirtazapine as prescribed. The doses associated with signs of toxicity were 15.00 mg (40 cats), 3.75 mg (25 cats), 7.50 mg (four cats), 30.00 mg (one cat), 18.75 mg (one cat), 11.25 mg (one cat), 5.80 mg (one cat) and 1.88 mg (one cat). For cats with available information, the onset of clinical signs ranged from 15 mins to 3 h, and time to resolution of clinical signs ranged from 12-48 h. Conclusions and relevance The greater number of adverse effects at 3.75 mg rather than 1.88 mg suggests that the latter may be a more appropriate starting dose for stimulating appetite while limiting toxicity. The benefit of dispensing exact doses of mirtazapine is implied given the likelihood of accidental administration of a full tablet (15 mg) and the resulting toxicity.
[Mh] Termos MeSH primário: Estimulantes do Apetite/toxicidade
Doenças do Gato/epidemiologia
Mianserina/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Doenças do Gato/induzido quimicamente
Gatos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/veterinária
Feminino
Masculino
Mianserina/toxicidade
Centros de Controle de Intoxicações
Estudos Retrospectivos
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Appetite Stimulants); 250PJI13LM (Mianserin); A051Q2099Q (mirtazapine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150801
[St] Status:MEDLINE
[do] DOI:10.1177/1098612X15599026



página 1 de 46 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde